Emergent Biosolutions Inc. Stock
A loss of -1.200% shows a downward development for Emergent Biosolutions Inc..
Emergent Biosolutions Inc. is currently one of the favorites of our community with 9 Buy predictions and no Sell predictions.
With a target price of 14 € there is a positive potential of 43.97% for Emergent Biosolutions Inc. compared to the current price of 9.72 €.
Our community identified positive and negative aspects for Emergent Biosolutions Inc. stock for the coming years. 1 users see the criterium "Company culture" as a plus for the Emergent Biosolutions Inc. stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Emergent Biosolutions Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
S********** s********
?
C******** o* t** e**********
Cons
?
B****
?
W********* I********* f** t** n*** y****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Emergent Biosolutions Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Emergent Biosolutions Inc. | -1.200% | -4.993% | 4.245% | 16.847% | 24.795% | -14.023% | -86.009% |
| Ironwood Pharmaceuticals | -2.550% | 4.795% | 19.531% | -8.383% | -27.143% | -73.167% | -68.934% |
| Novocure Ltd | -1.160% | 9.135% | 15.722% | -60.508% | -61.023% | -84.133% | -91.990% |
| Iovance Biotherapeutics Inc. | 0.650% | -0.393% | -14.490% | -75.357% | -72.809% | -71.362% | -95.447% |
Comments
Emergent Biosolutions (NYSE:EBS) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating.
Show more
Ratings data for EBS provided by MarketBeat
Emergent Biosolutions (NYSE:EBS) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating.
Show more
Ratings data for EBS provided by MarketBeat
Emergent Biosolutions (NYSE:EBS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Show more
Ratings data for EBS provided by MarketBeat